Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study

BACKGROUND AND OBJECTIVE: AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed for the treatment of heart failure. The current phase I study was conducted to evaluate the pharmacokinetics and safety of a single-dose 200-mg capsule formulation of AMG 986 relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Ashit, Kiang, Y.-H., Saw, Robert E., Cheng, Guilong Charles, Mather, Omar, Vega, Silvia, Hellawell, Jennifer, Lee, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167409/
https://www.ncbi.nlm.nih.gov/pubmed/35412220
http://dx.doi.org/10.1007/s40268-022-00388-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167409/
https://www.ncbi.nlm.nih.gov/pubmed/35412220
http://dx.doi.org/10.1007/s40268-022-00388-1

Ejemplares similares